 Home > Active Ingredient News > Antitumor Therapy > JCO: Using PET imaging to evaluate the significance of early treatment response to the prognosis of esophageal/esophageal-gastric junction cancer

JCO: Using PET imaging to evaluate the significance of early treatment response to the prognosis of esophageal/esophageal-gastric junction cancer

 Last Update: 2021-06-10
 Source: Internet
 Author: User

Tags

5 fluorouracil

cell gene therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

With the increasing incidence of esophagus and esophagogastric junction (EGJ) adenocarcinoma, the global burden of such malignant tumors is expected to increase sharply in the next decade, so more effective treatments are urgently needed.

The purpose of this study is to evaluate the early assessment of chemotherapy responsiveness through positron emission tomography (PET) imaging in customizing treatment strategies in patients with adenocarcinoma at the esophagus and esophagogastric junction.

After baseline PET, the patients were randomly divided into two groups and received two different induction chemotherapy regimens: FOLFOX regimen (modified oxaliplatin, leucovorin, and fluorouracil) or CP regimen (carboplatin-paclitaxel).

Prognosis of patients with and without response after induction chemotherapy

A total of 241 eligible patients received the protocol treatment, of which 225 had evaluable repeat PET examinations.

The pCR rate of patients who did not respond to PET after FOLFOX induction chemotherapy after switching to CP chemotherapy (n=39) was 18.

Prognosis of patients with or without response after induction therapy with different regimens

With a median follow-up of 5.

It is effective to use PET imaging as a biomarker to evaluate the early response of individualized treatment of adenocarcinoma patients at the esophagus and esophagogastric junction.

Original source:

Goodman Karyn A,Ou Fang-Shu,Hall Nathan C et al.

Randomized Phase II Study of PET Response- Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.